HemoShear is a biotechnology company focused on discovering novel biological targets and developing drugs to treat children’s rare metabolic disorders.
HemoShear's goal is to discover drugs that save the lives of children who are born with metabolic defects and are unable to sustain basic biochemical processes necessary for life.
HemoShear was founded in 2008 by Jim Powers, Brian Wamhoff, and Brett R. Blackman. The company is headquartered in Charlottesville, Virginia.
HemoShear's drug discovery platform, REVEAL-Tx™, enables the Company's scientists to create best-in-class, biologically relevant human disease models to uncover the underlying mechanisms of disease, translate those discoveries into drug targets, and select candidates that may treat patients successfully.
HemoShear also has exclusive partnerships to identify novel therapeutic approaches in nonalcoholic steatohepatitis (NASH) and an undisclosed rare liver disease with Takeda, and in gout with Horizon Therapeutics.
HemoShear is backed by Suvretta Capital, Janus Henderson Investors, Adage Capital Management LP and others. The company raised $40M in a Series A round on Feb 10, 2021. This brings HemoShear's total funding to $51.7M to date.